TRIM21 and interstitial lung disease: Prevalence of anti-MDA5 and anti-Ro-52 antibodies were significantly higher in IIM patients with RP-ILD than with C-ILD with respective incidence rates of 39.0 vs. 12.0% (P = 0.000) and 58.5 vs. 40.8% (P = 0.012) (Table 3).